Lorus Therapeutics Inc 

LRUSF:OTCQB

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
0.323 0.00   0.00%0.00%0178

Market data is delayed by at least 20 minutes.
Market is closed. As of 01:15 PM ET 1/17/2013
 
 
 

Latest News Headlines for Lorus Therapeutics Inc

Lorus Therapeutics Reports Second Quarter Results for Fiscal Year 2013
3 days 23 hours 17 minutes ago - Marketwire
Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three and six months ended November 30, 2012.
Lorus Therapeutics Reports Second Quarter Results for Fiscal Year 2013
3 days 23 hours 17 minutes ago - Marketwire Canada
Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three and six months ended November 30, 2012.
Lorus Therapeutics announces dose escalation of Phase I cancer study
7 days 9 hours 10 minutes ago - Datamonitor
Lorus Therapeutics Inc., a biopharmaceutical company, has announced that its Phase I clinical study of LOR-253 has escalated to the target dose level based on predicted and observed clinical effects without limitation by toxicity.
View more recent headlines
 
 
 
Company Background
Lorus Therapeutics Inc. (Lorus) is a biopharmaceutical company. The Company is a discovery, research and clinical development-stage company with a focus on cancer drugs. The Company has an active portfolio, including small molecules (LOR-253/LOR-500) and an immunotherapy (IL-17E). Lorus has worked to establish a marketable anticancer product pipeline, with products in various stages of development ranging from discovery and pre-clinical to a product available to start a Phase III clinical trial. Lorus has one subsidiary, NuChem Pharmaceuticals Inc. (NuChem).

Bid/Size
-- / --
Ask/Size
-- / --
Price Open
0.00
Previous Close
0.323
Day High
0.00
Day Low
0.00
52wk High/Date
0.595 / 5/1/2012
52wk Low/Date
0.1701 / 2/2/2012
% off 52wk High
-45.71%
% off 52wk Low
89.89%
Beta (5 Yr)
1.5
Market Capitalization
13.6M
Shares Outstanding
42.3M
Volatility Avg
0.00
EPS(TTM)
-0.17
P/E Ratio
Not Meaningful
Dividend Announcement
--
Yield
0.00%
Ex-Date
--
Date of Record
--
Payable
0.00 - --
Payable Date
--
Last Trade as of 1/17/2013 1:13 PM ET
 
 
 

LRUSF Lorus Therapeutics Inc vs. Peers

Peers 
LRUSF
Lorus Therapeutics Inc
6.25%
Celgene Corporation
25.13%
Biogen Idec Inc.
-1.81%
ISIS Pharmaceuticals, Inc.
35.73%
Idera Pharmaceuticals Inc
-15.60%
LRUSF
Lorus Therapeutics Inc
0.00%
Celgene Corporation
--
Biogen Idec Inc.
--
ISIS Pharmaceuticals, Inc.
--
Idera Pharmaceuticals Inc
--
LRUSF
Lorus Therapeutics Inc
0.00%
Celgene Corporation
1.87%
Biogen Idec Inc.
0.39%
ISIS Pharmaceuticals, Inc.
1.34%
Idera Pharmaceuticals Inc
-1.49%
Compare these stocks